Advanced epithelial ovarian cancer frequently presents with peritoneal dissemination and massive accumulation of malignant peritoneal fluid. In this setting, malignant ascites T-cell dysfunction represents a major therapeutic roadblock that compromises both endogenous immune surveillance and modern immunotherapies. While clinicians previously viewed ascites simply as an obstructive mechanical complication, modern translational research confirms it is a highly active, immunosuppressive microenvironment. Furthermore, this fluid contains substantial quantities of free fatty acids, phospholipids, and complex lipid mediators. These lipid fractions directly interact with infiltrating immune cells, rendering cytotoxic lymphocytes hyporesponsive. Consequently, understanding the metabolic mechanisms underpinning this local immunosuppression is crucial for improving patient outcomes.

Lipid Overload Driving Malignant Ascites T-cell Dysfunction

Malignant ascites provides an environment rich in bioactive lipids that continuously bathe tumour cells and infiltrating lymphocytes. When non-malignant naive or memory T cells enter this peritoneal exudate, they undergo profound phenotypic changes. Specifically, unesterified cholesterol, oxidized low-density lipoproteins, and specific phosphatidylcholine species accumulate rapidly within T cells. Consequently, cellular lipid transport pathways become overwhelmed. Rather than utilizing these abundant lipids as energy substrates, lymphocytes experience severe lipotoxicity. In addition, excess intracellular lipid accumulation disrupts homeostatic membrane fluidity and compromises normal structural organisation. Therefore, this sustained lipid stress impairs the capacity of T cells to mount effective immune responses against ovarian carcinoma cells. As a result, the peritoneal space transforms into a protected niche where neoplastic cells proliferate freely despite dense immune cell infiltration.

Transcriptomic Reprogramming and Metabolic Exhaustion Pathways

Recent transcriptomic profiling of T cells exposed to acellular ascites demonstrates widespread alterations in their metabolic gene expression. Most notably, researchers observed an upregulation of genes governing cholesterol efflux alongside signatures of incomplete fatty acid oxidation. In healthy activated T cells, balanced mitochondrial beta-oxidation provides sustained ATP synthesis to support cytokine production and proliferative burst. However, malignant ascites forces T cells into an aberrant metabolic programme that closely mimics classical exhaustion states. Furthermore, the accumulation of toxic lipid intermediates induces chronic cellular stress pathways and mitochondrial structural defects. Consequently, lymphocytes experience bioenergetic crisis and redox imbalances. Because these alterations occur independently of classical immune checkpoint upregulation, conventional anti-PD-1 or anti-CTLA-4 monotherapies frequently fail in this peritoneal compartment. Thus, metabolic reprogramming directly determines functional exhaustion.

Disrupted TCR Signalling and Membrane Dynamics

Beyond transcriptomic changes, ascites-associated lipids profoundly impair canonical T-cell receptor signalling at the plasma membrane. Under normal conditions, antigen encounter triggers rapid clustering of the T-cell receptor complex and recruitment of key tyrosine kinases. However, excess lipid uptake alters the composition of nanoscale lipid rafts within the plasma membrane bilayer. Consequently, early proximal phosphorylation events, such as the activation of ZAP70 and CD3-zeta chains, drop markedly upon T-cell stimulation. Furthermore, this signalling blockade selectively impairs downstream activation markers. While cytokine-driven IL-2 receptor alpha chain expression remains relatively unaltered, critical co-stimulatory receptors like CD137 show profound suppression. Therefore, lymphocytes fail to sustain proliferative signals or generate robust cytotoxic granules. In contrast, removing lipid fractions from ascites restores ZAP70 phosphorylation and rescues CD137 expression, demonstrating the reversibility of this immune defect.

Impact on Bispecific T-cell Engager Cytotoxicity

Locoregional immunotherapies, particularly bispecific T-cell engagers targeting epithelial cell adhesion molecule, represent an innovative strategy for controlling peritoneal carcinomatosis. Nevertheless, malignant ascites creates a hostile barrier that severely limits their efficacy. In experimental cocultures of ovarian cancer cells and primary T cells, untreated malignant ascites completely abolishes BiTE-mediated tumour cell lysis. Furthermore, production of key antitumour effector cytokines, including interferon-gamma and tumour necrosis factor-alpha, drops precipitously. Conversely, targeted depletion of lipids from the ascites fluid fully reinstates BiTE-induced cytotoxicity. In addition, lipid depletion restores robust interferon-gamma secretion and granzyme-mediated apoptosis. These findings demonstrate that the lack of efficacy in locoregional BiTE clinical trials does not stem from target antigen loss or intrinsic T-cell defects. Instead, environmental lipids represent the primary barrier preventing durable therapeutic responses.

Translational Strategies and Overcoming Metabolic Barriers

Recognizing lipid-induced immune paralysis offers actionable therapeutic avenues for gynaecological oncologists. Because physical removal or pharmacological modulation of ascites lipids rescues lymphocyte function, combination regimens show substantial promise. For example, pairing locoregional BiTE infusions with lipid-scavenging nanoparticles or pharmacological inhibitors of scavenger receptors could shield T cells from lipotoxic stress. Similarly, modulating cellular lipid uptake transporters, such as CD36 or SCARB1, may protect infiltrating lymphocytes against metabolic overload. Moreover, systemic metabolic interventions that enhance complete mitochondrial fatty acid oxidation could improve T-cell endurance within hostile peritoneal fluid. Thus, addressing the biochemical environment alongside immune receptor engagement represents the next frontier in ovarian cancer immunotherapy. Future clinical trials must incorporate metabolic cotreatments to maximize the curative potential of biological therapies in advanced disease.

Frequently Asked Questions

What causes malignant ascites T-cell dysfunction in ovarian cancer?

Malignant ascites contains high levels of unesterified cholesterol and bioactive phospholipids. When cytotoxic T cells absorb these excessive lipids, they undergo significant metabolic reprogramming. This metabolic stress triggers incomplete fatty acid oxidation, enhances cholesterol efflux, and alters plasma membrane composition. Consequently, proximal T-cell receptor signalling pathways become impaired, leading to functional immune exhaustion and loss of antitumour cytotoxicity.

How do ascites lipids impair bispecific T-cell engager efficacy?

Bispecific T-cell engagers require functional T-cell receptor machinery to crosslink immune cells to tumour antigens. Ascites lipids disrupt the nanoscale clustering of membrane receptors and inhibit key signalling kinases like ZAP70. As a result, T cells fail to produce interferon-gamma or release cytolytic perforin and granzymes, completely abolishing the tumour-killing efficacy of the engager construct.

Can reversing lipid accumulation restore local antitumour immune responses?

Yes, experimental evidence confirms that depleting lipid fractions from malignant ascites restores antitumour immunity. Removing these inhibitory lipids rescues ZAP70 phosphorylation, normalizes CD137 co-stimulatory receptor expression, and reactivates interferon-gamma production. Furthermore, lipid clearance completely reinstates BiTE-mediated cytotoxicity against ovarian cancer cells, supporting combination therapies that merge metabolic modulation with immunotherapy.

Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult qualified healthcare professionals before making clinical decisions. Clinical management of ovarian cancer and malignant ascites requires multidisciplinary evaluation based on validated clinical trial data and individual patient characteristics. Refer to the latest local and national guidelines for clinical practice.

References

Wan PK et al. Lipid-rich ascites reprograms the T cell lipid metabolic transcriptome to drive dysfunction. Cancer Immunol Res. 2026 Nov 13. doi: 10.1158/2326-6066.CIR-26-0206. PMID: 43023987.

Brown EG, Compeer EB, Gan Z, et al. Lipids in ovarian cancer ascites impair T cell activation by disrupting TCR dynamics. Nat Metab. 2026;8(7):1508-1527.

Slattery K, Haigis MC, Lynch L, et al. Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer. Sci Immunol. 2025;10(95):eadl4372.